A Health Podyssey

Medicaid vs. 340B: A Drug Pricing Clash (Sayeh Nikpay)


Listen Later

Health Affairs' Rob Lott interviews Sayeh Nikpay of the University of Minnesota about her recent paper exploring how The Medicaid Drug Rebate Program and the 340B Program interact in ways that can unintentionally increase costs, the adoption of cost-saving strategies to mitigate these interactions, and how policymakers can act to balance Medicaid savings with revenue impacts on 340B-participating safety-net providers.

Order the January 2026 issue of Health Affairs.

Currently, more than 70 percent of our content is freely available - and we'd like to keep it that way. With your support, we can continue to keep our digital publication Forefront and podcast

...more
View all episodesView all episodes
Download on the App Store

A Health PodysseyBy Health Affairs

  • 4.9
  • 4.9
  • 4.9
  • 4.9
  • 4.9

4.9

41 ratings


More shows like A Health Podyssey

View all
Radiolab by WNYC Studios

Radiolab

43,913 Listeners

Freakonomics Radio by Freakonomics Radio + Stitcher

Freakonomics Radio

32,252 Listeners

The New Yorker Radio Hour by WNYC Studios and The New Yorker

The New Yorker Radio Hour

6,964 Listeners

Planet Money by NPR

Planet Money

30,719 Listeners

Death, Sex & Money by Slate Podcasts

Death, Sex & Money

7,710 Listeners

What the Health? From KFF Health News by KFF Health News

What the Health? From KFF Health News

498 Listeners

Interesting Times with Ross Douthat by New York Times Opinion

Interesting Times with Ross Douthat

7,261 Listeners

An Arm and a Leg by An Arm and a Leg

An Arm and a Leg

1,078 Listeners

Throughline by NPR

Throughline

16,479 Listeners

Tradeoffs by Tradeoffs

Tradeoffs

387 Listeners

Public Health On Call by The Johns Hopkins Bloomberg School of Public Health

Public Health On Call

630 Listeners

Health Affairs This Week by Health Affairs

Health Affairs This Week

30 Listeners

The Ezra Klein Show by New York Times Opinion

The Ezra Klein Show

16,482 Listeners

Not Otherwise Specified by NEJM Group

Not Otherwise Specified

66 Listeners

The Opinions by The New York Times Opinion

The Opinions

613 Listeners